[1]WOODCOCK J,LAVANGE L M. Master protocols to study multiple therapies,multiple diseases,or both[J]. N Engl J Med,2017,377(1):62-70.
[2]HYMAN D M,PUZANOV I,SUBBIAH V,et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. N Engl J Med,2015,373(8):726-736.
[3]MERIC-BERNSTAM F,HURWITZ H,RAGHAV K P S,et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway):an updated report from a multicentre,open-label,phase 2a,multiple basket study[J]. Lancet Oncol,2019,20(4):518-530.
[4]KIM E S,HERBST R S,WISTUBA I I,et al. The BATTLE trial:personalizing therapy for lung cancer[J]. Cancer Discov,2011,1(1):44-53.
[5]MIDDLETON G,FLETCHER P,POPAT S,et al. The national lung matrix trial of personalized therapy in lung cancer[J]. Nature,2020,583(7818):807-812.
[6]DE FRANCO E,FLANAGAN S E,HOUGHTON J A,et al. The effect of early,comprehensive genomic testing on clinical care in neonatal diabetes:an international cohort study[J]. Lancet,2015,386(9997):957-963.